KB-1116

TRX518-hIgG4-S228P

45197

Home » Antibodies » TRX518-hIgG4-S228P

Background of TRX518-hIgG4-S228P

The tumor necrosis factor receptor GITR is expressed at high levels on regulatory T cells (Tregs) and up-regulated on activated T cells. TRX518 is a fully humanized IgG1 anti-huGITR Mab. TRX518 bound to GITR on CD4+ and CD8+ naïve and memory T cells, B cells, NK cells, NKT cells, monocytes, and macrophages. TRX518 blocked the interaction of GITR with its ligand and enhanced the cytotoxicity of NK cells.

Specifications

Catalog Number	KB-1116
Antibody Name	TRX518-hIgG4-S228P
Isotype	Human IgG4-S228P, kappa
FC Muations	S228P
Target	GITR
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

M. Rosenzweig et al. Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.. JCO 28, e13028-e13028(2010).
Davar D, Zappasodi R, Wang H, Naik GS, Sato T, Bauer T, Bajor D, Rixe O, Newman W, Qi J, Holland A, Wong P, Sifferlen L, Piper D, Sirard CA, Merghoub T, Wolchok JD, Luke JJ. Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clin Cancer Res. 2022 Sep 15;28(18):3990-4002.